by Combat Cancer | Nov 22, 2023 | Hyperthermia
In the third of a series of articles charting the history of hyperthermic treatment for bladder cancer, Johannesburg-based urologist Dr Steven Cornish looks at the development of different intravesical drug treatments for hyperthermic chemotherapy, including some...
by Combat Cancer | Nov 16, 2023 | News
Fascinating research into the link between pancreatic ductal adenocarcinoma (PDAC) risk and elevated insulin levels has just been published in Cell Metabolism (Zhang et al). For the first time, we’ve now got a detailed explanation of why people with obesity and...
by Combat Cancer | Nov 9, 2023 | News
More than half a million new cases of bladder cancer are diagnosed globally each year, with 200,000 deaths annually. Around 75% of patients present with non-muscle-invasive bladder cancer (NMIBC), with maintenance BCG regarded as the best bladder-sparing treatment for...
by Combat Cancer | Nov 2, 2023 | News
Breaking news! A new study just published in International Urology and Nephrology (Pazir et al) demonstrates that HIVEC with mitomycin C has a similar oncological efficacy and safety profile to standard BCG therapy in high-risk, non-muscle-invasive bladder cancer...
by Combat Cancer | Oct 26, 2023 | News
In the UK, bladder cancer quietly ranks among the top ten most common cancers for both men and women. Despite its prevalence, public awareness remains dismally low, making it a low-priority issue on the public health agenda. Bladder cancer, often dubbed the...
Recent Comments